Submit the Expanded Immunohematology microarray for CE mark
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- November 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company now expects to make this CE mark submission in the second quarter of calendar year 2021.”
What we found
Evidence strength A What the grades mean
The company committed to a Q2 2021 submission for the CE mark of the expanded MosaiQ IH Microarray, but filings confirm the submission did not occur until November 2021.
-
A Quotient Ltd 10-Q filed 2021-11-16
“We submitted the European regulatory dossier for the expanded MosaiQ IH Microarray in November 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Rollout
- Indicative materiality
- Low rules
- Action
- Submit
- Deliverable
- CE mark submission
- Where
- Europe
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Quotient Ltd? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C596946-022756 · Corrections policy